Drug Target Review

APRIL 17, 2023

This ebook deep dives into adoption and optimization of label-free hit-to-lead (HTL) technologies, including advanced surface plasmon resonance (SPR) applications for hit identification and validation.

Pharmaceutical Companies 52

Pharmaceutical Companies Laboratories Drugs Drug Research 52

DrugBank

MARCH 22, 2024

These data sources are known for being highly referenced and usable for specific research activities; further yet, a number of recognizable open sources, along with their identifiers, are considered industry standard resources.

Licensing 98

Licensing Licensing Research Clinical Trials 98

Advarra

AUGUST 16, 2022

The Orphan Drug Act of 1983 was instrumental in changing the number of orphan drugs approved in the U.S. The law established the Office of Orphan Products Development , providing financial incentives for pharmaceutical companies to develop orphan drugs and making it more viable to invest in orphan drug research and development.

Disease 52

Disease Clinical Trials FDA Approval FDA 52

Codon

JANUARY 21, 2024

People are hesitant to do this because it's not a particularly flashy disease to research, nor is this population the focus of major pharmaceutical companies. So if you're a researcher, you can pour your heart and soul into a hepatitis C vaccine, and it probably won't ever get tested. So you have to do a field study.

Vaccine 126

Vaccine Trials Disease Treatment 126

The Pharma Data

NOVEMBER 10, 2020

Dr. Liu shared his over 30 years of R&D experience in drug development both in the global pharmaceutical companies and world renowned scientific research institutions. Yong-Jun Liu , the newly appointed President of Innovent also made his first public appearance on the virtual R&D day.

Biosimilars 52

Biosimilars Clinical Trials International Clinical Development 52

DrugBank

FEBRUARY 12, 2025

CMap utilizes gene expression profiles to connect drugs, genes, and diseases, enabling researchers to identify potential repurposing candidates based on their transcriptional signatures. We invite researchers, pharmaceutical companies, and academic institutions to join us to unlock the full potential of drug repurposing.

Cell Based Assays 52

Cell Based Assays Drugs Pharmacokinetics Disease 52

Drug Target Review

FEBRUARY 11, 2025

Drug development: addressing complexity and success rates Drug development is a complex and expensive process, requiring multidisciplinary expertise and high-risk financial investments. The major hurdles that pharmaceutical companies face are long lead times, high costs and a low probability of success (PoS).

Drug Development 59

Drug Development Bioinformatics Drugs Small Molecule 59